Analyst Maintains Buy on Microbix as China Antigen Sales Normalize and Revenue Growth RecoversTip Ranks·Aug 16 at 04:05 AMMBX-0.03%
MBX Biosciences posts corporate presentation on precision peptide programs for endocrine, metabolic diseasesPUBT·Aug 6 at 07:11 AMMBX-0.03%
MBX Biosciences Q2 FY26 net loss widens to $37.1 million; R&D expenses rise to $31 millionPUBT·Aug 6 at 07:08 AMMBX-0.03%
Microbix updates financial calendar with Q3 fiscal 2026 results release and investor webinarPUBT·Aug 6 at 06:17 AMMBX-0.03%
MBX Biosciences (NASDAQ:MBX) Sets New 52-Week High on Analyst UpgradeMarket Beat·Jul 30 at 03:40 PMMBX-0.03%RY+0.01%
MBX Biosciences, Inc. (NASDAQ:MBX) Receives Average Rating of "Moderate Buy" from AnalystsMarket Beat·Jul 29 at 01:44 AMMBX-0.03%
Mizuho Securities Sticks to Its Buy Rating for MBX Biosciences, Inc. (MBX)Tip Ranks·Jul 28 at 05:35 PMMBX-0.03%
